Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
Provided By GlobeNewswire
Last update: Nov 20, 2024
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation
Pivotal trials of NX-5948 are planned to initiate in 2025
Read more at globenewswire.com
